{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:21:23Z","timestamp":1792041683717,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clinicians, researchers, and patients alike would greatly benefit from more accessible and inexpensive biomarkers for neural \u03b2-amyloid (A\u03b2). We aimed to assess the performance of fully automated plasma A\u03b2 immunoassays, which correlate significantly with immunoprecipitation mass spectrometry assays, in predicting brain A\u03b2 status as determined by visual read assessment of amyloid positron emission tomography (PET).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The plasma A\u03b242\/A\u03b240 ratio was measured using a fully automated immunoassay platform (HISCL series) in two clinical studies (discovery and validation studies). The discovery and validation sample sets were retrospectively and randomly selected from participants with early Alzheimer\u2019s disease (AD) identified during screening for the elenbecestat Phase 3 program.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 197 participants in the discovery study (mean [SD] age 71.1 [8.5] years; 112 females) and 200 in the validation study (age 70.8 [7.9] years; 99 females). The plasma A\u03b242\/A\u03b240 ratio predicted amyloid PET visual read status with areas under the receiver operating characteristic curves of 0.941 (95% confidence interval [CI] 0.910\u20130.973) and 0.868 (95% CI 0.816\u20130.920) in the discovery and validation studies, respectively. In the discovery study, a cutoff value of 0.102 was determined based on maximizing the Youden Index, and the sensitivity and specificity were calculated to be 96.0% (95% CI 90.1\u201398.9%) and 83.5% (95% CI 74.6\u201390.3%), respectively. Using the same cutoff value, the sensitivity and specificity in the validation study were calculated to be 88.0% (95% CI 80.0\u201393.6%) and 72.0% (95% CI 62.1\u201380.5%), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The plasma A\u03b242\/A\u03b240 ratio measured using the HISCL series achieved high accuracy in predicting amyloid PET status. Since our blood-based immunoassay system is less invasive and more accessible than amyloid PET and cerebrospinal fluid testing, it may contribute to the diagnosis of AD in routine clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-01029-0","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T09:02:46Z","timestamp":1655974966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Fully automated and highly specific plasma \u03b2-amyloid immunoassays predict \u03b2-amyloid status defined by amyloid positron emission tomography with high accuracy"],"prefix":"10.1186","volume":"14","author":[{"given":"Kazuto","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Ishiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Arimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Kawahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiko","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutaka","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Irino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Verbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Dhadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Niiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"1029_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","volume":"11","author":"C Qiu","year":"2009","unstructured":"Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer\u2019s disease Occurrence, determinants and strategies toward intervention. Dialogues Clin Neurosci. 2009;11:111\u201328. https:\/\/doi.org\/10.31887\/DCNS.2009.11.2\/cqiu (Published online first: 2009\/07\/10).","journal-title":"Dialogues Clin Neurosci"},{"key":"1029_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer\u2019s disease. Alzheimers Dement. 2007;3:186\u201391. https:\/\/doi.org\/10.1016\/j.jalz.2007.04.381.","journal-title":"Alzheimers Dement"},{"key":"1029_CR3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"LE Hebert","year":"2013","unstructured":"Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010\u20132050) estimated using the 2010 census. Neurology. 2013;80:1778\u201383. https:\/\/doi.org\/10.1212\/WNL.0b013e31828726f5.","journal-title":"Neurology"},{"key":"1029_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"T Iwatsubo","year":"1994","unstructured":"Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A\u03b242(43) and A\u03b240 in senile plaques with end-specific A\u03b2 monoclonals: evidence that an initially deposited species is A\u03b242(43). Neuron. 1994;13:45\u201353. https:\/\/doi.org\/10.1016\/0896-6273(94)90458-8.","journal-title":"Neuron"},{"key":"1029_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: A prospective cohort study. Lancet Neurol. 2013;12:357\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(13)70044-9.","journal-title":"Lancet Neurol"},{"key":"1029_CR6","doi-asserted-by":"publisher","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet:2021. https:\/\/doi.org\/10.1016\/s0140-6736(20)32205-4","DOI":"10.1016\/s0140-6736(20)32205-4"},{"key":"1029_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708[Publishedonlinefirst:2021\/03\/16]","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708[Publishedonlinefirst:2021\/03\/16].","journal-title":"N Engl J Med"},{"key":"1029_CR8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat Med. 2021;27:1187\u201396. https:\/\/doi.org\/10.1038\/s41591-021-01369-8.","journal-title":"Nat Med"},{"key":"1029_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80. https:\/\/doi.org\/10.1186\/s13195-021-00813-8.","journal-title":"Alzheimers Res Ther"},{"key":"1029_CR10","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","volume":"181","author":"B Dunn","year":"2021","unstructured":"Dunn B, Stein P, Cavazzoni P. Approval of Aducanumab for Alzheimer disease-the FDA\u2019s perspective. JAMA Intern Med. 2021;181:1276\u20138. https:\/\/doi.org\/10.1001\/jamainternmed.2021.4607.","journal-title":"JAMA Intern Med"},{"key":"1029_CR11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: Appropriate use recommendations. J Prev Alzheimers Dis. 2021;8:398\u2013410. https:\/\/doi.org\/10.14283\/jpad.2021.41.","journal-title":"J Prev Alzheimers Dis."},{"key":"1029_CR12","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. ADUHELM. Reference. ID; 2021. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761178. 4822820"},{"key":"1029_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating Aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79:13\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4161.","journal-title":"JAMA Neurol"},{"key":"1029_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3233\/ADR-190143","volume":"4","author":"S Hameed","year":"2020","unstructured":"Hameed S, Fuh JL, Senanarong V, Ebenezer EGM, Looi I, Dominguez JC, et al. Role of fluid biomarkers and PET imaging in early diagnosis and its clinical implication in the management of Alzheimer\u2019s disease. J Alzheimers Dis Rep. 2020;4:21\u201337. https:\/\/doi.org\/10.3233\/ADR-190143 (Published online first: 2020\/03\/25).","journal-title":"J Alzheimers Dis Rep"},{"key":"1029_CR15","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005072-199710000-00002","volume":"56","author":"BT Hyman","year":"1997","unstructured":"Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095\u20137. https:\/\/doi.org\/10.1097\/00005072-199710000-00002.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1029_CR16","doi-asserted-by":"publisher","first-page":"175628641988881","DOI":"10.1177\/1756286419888819[Publishedonlinefirst:2020\/01\/04]","volume":"12","author":"M Mil\u00e0-Alom\u00e0","year":"2019","unstructured":"Mil\u00e0-Alom\u00e0 M, Su\u00e1rez-Calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer\u2019s disease. Ther Adv Neurol Disord. 2019;12:1756286419888819. https:\/\/doi.org\/10.1177\/1756286419888819[Publishedonlinefirst:2020\/01\/04].","journal-title":"Ther Adv Neurol Disord"},{"key":"1029_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-89004-x","volume":"11","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, Verberk IMW, Vanbrabant J, Koelewijn A, Heijst H, Scheltens P, et al. Highly specific and ultrasensitive plasma test detects Abeta(1\u201342) and Abeta(1\u201340) in Alzheimer\u2019s disease. Sci Rep. 2021;11:1\u201342. https:\/\/doi.org\/10.1038\/s41598-021-89004-x.","journal-title":"Sci Rep."},{"key":"1029_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13041-019-0448-1","volume":"12","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer\u2019s disease. Mol Brain. 2019;12:26. https:\/\/doi.org\/10.1186\/s13041-019-0448-1.","journal-title":"Mol Brain"},{"key":"1029_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF A \u03b2 42\/A \u03b2 40 and A \u03b2 42\/A \u03b2 38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154\u201365. https:\/\/doi.org\/10.1002\/acn3.274.","journal-title":"Ann Clin Transl Neurol"},{"key":"1029_CR20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol. 2019;76:1060\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1632 (Published online first: 2019\/06\/25).","journal-title":"JAMA Neurol"},{"key":"1029_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554:249\u201354. https:\/\/doi.org\/10.1038\/nature25456 (Published online first: 2018\/02\/09).","journal-title":"Nature"},{"key":"1029_CR22","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93:1647-59-e59. https:\/\/doi.org\/10.1212\/WNL.0000000000008081 (Published online first: 2019\/08\/03).","journal-title":"Neurology"},{"key":"1029_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1074\/mcp.M500331-MCP200","volume":"5","author":"L Anderson","year":"2006","unstructured":"Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics. 2006;5:573\u201388. https:\/\/doi.org\/10.1074\/mcp.M500331-MCP200.","journal-title":"Mol Cell Proteomics"},{"key":"1029_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jim.2009.06.003","volume":"347","author":"AN Hoofnagle","year":"2009","unstructured":"Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods. 2009;347:3\u201311. https:\/\/doi.org\/10.1016\/j.jim.2009.06.003.","journal-title":"J Immunol Methods"},{"key":"1029_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.clinbiochem.2020.05.007","volume":"82","author":"DT Holmes","year":"2020","unstructured":"Holmes DT, Romney MG, Angel P, DeMarco ML. Proteomic applications in pathology and laboratory medicine: Present state and future prospects. Clin Biochem. 2020;82:12\u201320. https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.05.007 (Published online first: 2020\/05\/23).","journal-title":"Clin Biochem"},{"key":"1029_CR26","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allu\u00e9 JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78:1375\u201382. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3180.","journal-title":"JAMA Neurol"},{"key":"1029_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbrc.2021.08.066","volume":"576","author":"K Yamashita","year":"2021","unstructured":"Yamashita K, Watanabe S, Ishiki K, Miura M, Irino Y, Kubo T, et al. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for beta-amyloid (1\u201340) and (1\u201342) in plasma samples. Biochem Biophys Res Commun. 2021;576:22\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2021.08.066 (Published online first: 2021\/09\/04).","journal-title":"Biochem Biophys Res Commun"},{"key":"1029_CR28","doi-asserted-by":"publisher","first-page":"10144","DOI":"10.1038\/s41598-019-46548-3","volume":"9","author":"M Goto","year":"2019","unstructured":"Goto M, Chamoto K, Higuchi K, Yamashita S, Noda K, Iino T, et al. Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma. Sci Rep. 2019;9:10144. https:\/\/doi.org\/10.1038\/s41598-019-46548-3.","journal-title":"Sci Rep"},{"key":"1029_CR29","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3892\/ol.2020.11371","volume":"19","author":"M Miura","year":"2020","unstructured":"Miura M, Fujinami N, Shimizu Y, Mizuno S, Saito K, Suzuki T, et al. Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery. Oncol Lett. 2020;19:2657\u201366. https:\/\/doi.org\/10.3892\/ol.2020.11371.","journal-title":"Oncol Lett"},{"key":"1029_CR30","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1038\/s41598-021-84387-3","volume":"11","author":"K Noda","year":"2021","unstructured":"Noda K, Matsuda K, Yagishita S, Maeda K, Akiyama Y, Terada-Hirashima J, et al. A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Sci Rep. 2021;11:5198. https:\/\/doi.org\/10.1038\/s41598-021-84387-3.","journal-title":"Sci Rep"},{"key":"1029_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"key":"1029_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"1029_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e1. https:\/\/doi.org\/10.1016\/j.jalz.2014.07.003.","journal-title":"Alzheimers Dement"},{"key":"1029_CR34","doi-asserted-by":"publisher","unstructured":"Roberts C, Kaplow J, Giroux M. Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program. The Journal of Prevention of Alzheimer's Disease. 2021:1\u20136. https:\/\/doi.org\/10.14283\/jpad.2021.4","DOI":"10.14283\/jpad.2021.4"},{"issue":"Suppl1","key":"1029_CR35","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.14283\/jpad.2021.57","volume":"8","author":"D Verbel","year":"2021","unstructured":"Verbel D, Gee M, Kaplow J, Kanekiyo M, Irizarry M, Dhadda S, et al. Prediction of Brain Amyloid Pathology Using plasma A\u03b242\/40 Ratio Measured Using the C2N PrecivityAD Test in the MissionAD Study Samples, CTAD presentation. J Prev Alzheimers Dis. 2021;8(Suppl1):S68. https:\/\/doi.org\/10.14283\/jpad.2021.57.","journal-title":"J Prev Alzheimers Dis"},{"key":"1029_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345. https:\/\/doi.org\/10.2307\/2531595.","journal-title":"Biometrics"},{"key":"1029_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3233\/JAD-170327[Publishedonlinefirst:2017\/09\/05]","volume":"60","author":"E Niemantsverdriet","year":"2017","unstructured":"Niemantsverdriet E, Ottoy J, Somers C, De Roeck E, Struyfs H, Soetewey F, et al. The cerebrospinal fluid Abeta1-42\/Abeta1-40 ratio improves concordance with amyloid-PET for diagnosing Alzheimer\u2019s disease in a clinical setting. J Alzheimers Dis. 2017;60:561\u201376. https:\/\/doi.org\/10.3233\/JAD-170327[Publishedonlinefirst:2017\/09\/05].","journal-title":"J Alzheimers Dis"},{"key":"1029_CR38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","volume":"55","author":"P Lewczuk","year":"2017","unstructured":"Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo JL, Eusebi P, et al. Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;55:813\u201322. https:\/\/doi.org\/10.3233\/JAD-160722.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"1029_CR39","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","volume":"74","author":"S Janelidze","year":"2017","unstructured":"Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74(12):1492. https:\/\/doi.org\/10.1001\/jamaneurol.2017.2814.","journal-title":"JAMA Neurol"},{"key":"1029_CR40","doi-asserted-by":"publisher","unstructured":"Willemse EAJ, Tijms BM, Berckel BNM, Le Bastard N, Flier WM, Scheltens P, et al. Comparing CSF amyloid\u2012beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2021;13(1). https:\/\/doi.org\/10.1002\/dad2.12182","DOI":"10.1002\/dad2.12182"},{"key":"1029_CR41","doi-asserted-by":"publisher","first-page":"5086250","DOI":"10.1155\/2020\/5086250","volume":"2020","author":"AA Mamun","year":"2020","unstructured":"Mamun AA, Uddin MS, Bin Bashar MF, Zaman S, Begum Y, Bulbul IJ, et al. Molecular insight into the therapeutic promise of targeting APOE4 for Alzheimer\u2019s disease. Oxid Med Cell Longev. 2020;2020:5086250. https:\/\/doi.org\/10.1155\/2020\/5086250 (Published online first: 2020\/06\/09).","journal-title":"Oxid Med Cell Longev"},{"key":"1029_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13024-021-00451-6","volume":"16","author":"T West","year":"2021","unstructured":"West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, et al. A blood-based diagnostic test incorporating plasma A\u03b242\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. Mol Neurodegener. 2021;16:30. https:\/\/doi.org\/10.1186\/s13024-021-00451-6.","journal-title":"Mol Neurodegener"},{"key":"1029_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13195-021-00911-7","volume":"13","author":"H Jang","year":"2021","unstructured":"Jang H, Kim JS, Lee HJ, Kim CH, Na DL, Kim HJ, et al. Performance of the plasma A\u03b242\/A\u03b240 ratio, measured with a novel HPLC-MS\/MS method, as a biomarker of amyloid PET status in a DPUK-Korean cohort. Alzheimers Res Ther. 2021;13:179. https:\/\/doi.org\/10.1186\/s13195-021-00911-7.","journal-title":"Alzheimers Res Ther"},{"key":"1029_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","volume":"144","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum. Brain. 2021;144:325\u201339. https:\/\/doi.org\/10.1093\/brain\/awaa399.","journal-title":"Brain"},{"key":"1029_CR45","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78:1471\u201383. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671.","journal-title":"JAMA Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01029-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01029-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01029-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T09:04:40Z","timestamp":1655975080000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01029-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01029-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were conducted in accordance with the Declaration of Helsinki and after approval of the local ethics committees of the participating centers. All participants (or their legal representatives) provided written informed consent prior to enrolling in MissionAD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KY, MM, SW, KI, YA, JK, KS, TA, KH, YI, HN, SI, and TS were employees of Sysmex Corporation. TK is an employee of Sysmex R&D Center Americas Inc. KN is an employee of Eisai Co. Ltd. DV, AK, and SD are employees of Eisai, Inc. TY is a board member of Sysmex Corporation. AI received lectures and advisory fees from Eisai, Daiichi Sankyo, MSD, Biogen, Janssen, and Sysmex. AI has received research grants from Eisai, Daiichi Sankyo, MSD, Shionogi, Kyowa Kirin, and Abbvie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}